Daratumumab-Based Therapies in Patients With AL Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Abstract & Posters

Daratumumab-Based Therapies in Patients With AL Amyloidosis

key information

source: American Society of Clinical Oncology

year: 2018

authors: Jithma P. Abeykoon, Saurabh Zanwar, Shaji Kumar, Angela Dispenzieri, S. Vincent Rajkumar, Martha Lacy, David Dingli, Nelson Leung, Eli Muchtar, Wilson I. Gonsalves, Taxiarchis Kourelis, Francis Buadi, Robert A. Kyle, Morie A. Gertz, Prashant Kapoor

summary/abstract:

Background:

Treatment options for patients (pts) with relapsed/refractory (RR) AL amyloidosis are limited. Daratumumab (dara) has been approved as monotherapy (DMT) or combination therapy (DCT) for multiple myeloma (MM). Data for dara-based therapy (DBT) in AL are sparse.

Methods:

We studied pts with RR AL without coexisting MM seen at Mayo Clinic from 11/2015 to 02/2018 & treated with DBT. Hematologic response (HR) & organ response (OR) were defined per Consensus criteria. All time to event analyses were done from the time of DBT initiation. Pts with dFLC < 4 mg/dL at the time of start of DBT were considered non evaluable (NE) for HR other than disease progression. DCT included dara, pomalidomide & dexamethasone (dex) (35%), dara, lenalidomide & dex (26%), dara, bortezomib & dex (22%) & other DBT regimens (17%).

Results:

45 pts (DMT, n = 22; DCT, n = 23) received DBT; median age at DBT initiation was 64 years (range: 46-82). Data for HR assessment were available in 44 pts & 31 were evaluable for HR. HR & end points are outlined in Table 1. Among 13 NE pts, response improved to CR in 5 (38%) while remaining 8 continued to be NE. Of these 13 pts, 77% reached dFLC < 1 mg/dL at last follow up (FU). Cardiac, renal & liver involvement was observed in 59%, 43% & 7% of pts. Cardiac, renal and liver OR was 46%, 32%, 0%, respectively. At last FU, 31 pts were on DBT. Three (7%) pts had disease progression. Hematologic toxicity (HT) from DBT included anemia ≤2 grade (Gr = ) 69%, 3 Gr 3%; thrombocytopenia 1 Gr 38%; neutropenia ≤2 Gr21% &> 2 Gr 7%. Non-HTs included fatigue (23%), infusion reactions (21%), & treatment-emergent neuropathy (14%).

Conclusions:

DBT is safe & effective in heavily pretreated pts with AL. HR is achieved rapidly with DBT, particularly with DCT.

organization: Mayo Clinic, USA

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close